SBIR TOPIC 252 -COMMERCIALLY VIABLE SYNTHESIS OF MULTIFUNCTIONAL CANCER RECEPTOR
In this Phase I SBIR contract, Nanoparticle Biochem Inc (NBI) proposes to develop commercially viable synthetic methodology for the production of multifunctional gold Nanoparticle-bombesin conjugate. Gold Nanoparticle-bombesin (AuNP-BBN) conjugate is a pot ential clinical imaging and therapeutic agent for the detection and treatment of GRP receptors over-expressing prostate and breast cancers. Average size of AuNP-BBN nanoconjugates are 14 nm. AuNP-BBN conjugate was developed by the funds from NCI's cancer n anoscience and nanotechnology platform grant and it is licensed to Nanoparticle Biochem Inc. Currently available methodology can yield only 10 mg quantities of AuNP-BBN. Developing a commercially-viable strategy for synthesizing AuNP-BBN nanoconjugate woul d significantly help in performing preclinical cancer imaging efficacy studies in larger animal models and preclinical toxicity studies.
Small Business Information at Submission:
Principal Investigator:Anandhi Upendran
NANOPARTICLE BIOCHEM, INC.
2814 WILD PLUM CT. COLUMBIA, MO 65201
Number of Employees: